Patent · US Expired

Monoclonal antibodies selective for prostate cancer

US4970299A · kind A · utility

33Cited by
10References
4Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJul 3, 1986
Grant dateNov 13, 1990
Priority date
Expiry dateJul 3, 2006

Classification

  • Technology area (CPC Y)Emerging Cross-Sectional Technologies
  • CPC primaryY10S530/861
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Four monoclonal antibodies are found which selectively identify prostate cancer. These monoclonals are therefore useful in diagnosis, differential diagnosis and treatment of prostate cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.